Search Results for ""

“I think educating patients of what can happen and those are the symptoms you're really looking for to decrease this from getting to the severe level is like the sensory stuff. It's kind of your starting point and it progresses from there,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what nurses need to know about cancer- and treatment-related peripheral neuropathy. This episode is part of a series on cancer symptom management basics; the rest are linked below. 

“So much of this is just knowing what is their diagnosis, what medications are they on, what could be the root cause of this—where is their disease to begin with? There's really a lot of differential diagnosis and workup that has to be thought about, you know, when you're dealing with shortness of breath and pulmonary toxicities,” Beth Sandy, MSN, CRNP, OCN®, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about just a few of the pulmonary toxicities oncology nurses may encounter in patients receiving pharmaceutical cancer treatments. This episode is part of a series on cancer symptom management basics; the rest are linked below. 

“I can think of examples where I have two patients. They have the same diagnosis, but they have two different insurance companies, treatment plan’s the same. ‘Patient A’ isn't going to get the optimal treatment plan because their insurance company won't approve it. ‘Patient B’ is going to get the Cadillac version of this treatment plan, and what am I supposed to do about it,” Lucia D. Wocial, PhD, RN, FAAN, HEC-C, senior clinical ethicist in the John J. Lynch Center for Ethics at the MedStar Washington Hospital Center in Washington, DC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about how access-to-care issues can produce moral dilemmas for nurses and how to manage this.  

 “The search for daunorubicin’s sister really led to this discovery of doxorubicin, which is an analog with much greater activity. The discovery of doxorubicin can be coined kind of as, ‘one of the best drugs born in Milan, Italy.’ And after that, a few analogs were developed and tested, and two that we currently use today, are idarubicin and epirubicin,” Puja Patel, PharmD, BCOP, clinical oncology pharmacist at the Delnor Hospital Northwestern Medicine Cancer Center in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about anthracyclines and other antitumor antibiotics. This episode is part of a series about drug classes, which we’ll include a link to in the episode notes.

“AYAs are underrepresented in clinical trials and unfortunately have one of the highest rates of being uninsured of any population. So, this is really concerning for a lot of reasons and really impacts our ability to make a difference for their treatment and outcomes,” Stacy Whiteside, APRN, MS, CPNP-AC/PC, CPON®, nurse practitioner and fertility patient navigator in the Department of Hematology, Oncology, and Blood and Marrow Transplant at Nationwide Children’s Hospital in Columbus, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about increasing AYA enrollment in clinical trials. Whiteside is also the nursing representative for the Children’s Oncology Group (COG) AYA Committee. 

“A sense of belonging is what tithers us to those who share in our spaces that work with us. Belonging is fueled by a social connection, which is one of our basic human needs.  When you feel safe, supported and valued, you bring your full, authentic self to work and you're fully engaged to work collaboratively to deliver the best patient care and quite frankly, be the best teammate ever,” Kecia Boyd, DNP, RN, NEA-BC, AOCNS®, BMTCN®, director of inclusion, diversity, and equity in the department of nursing and patient care services at the Dana-Farber Cancer Institute in Boston, MA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about how nurses can contribute to a community of belonging in their workplace.  

“I think that there are certain agents that are so foundational in some diseases that they will remain. Whether they remain first-line, maybe not; maybe they’ll go to second line as we see things evolve with new agents. Some of these drugs have been very effective in the diseases in which they are used to treat patients. There’s a long term place in therapy for these, and I think that will still be using these,” Rowena Schwartz, PharmD, BCOP, FHOPA, known to many as “Moe,” professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, oncology clinical specialist at ONS, during a discussion about what oncology nurses need to know about antimetabolites. This episode is part of a series about drug classes, which we’ll include a link to in the episode notes. 

“Our top priorities really revolve around ensuring that everybody, regardless of their income, regardless of their gender, regardless of their race, regardless of where in the country they live, has access to the very best care for them and their family. And then ensuring that nurses have all of the education and training and support that they need to provide that care,” Jaimie Vickery, ONS’s director of government affairs and advocacy, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what the role of ONS’s lobbyist entails and what listeners should know about ONS’s 2023 advocacy work along with what’s ahead for 2024. 

“With the turnover rates where they’re at now, there’s no way we can keep thinking how we did in the past—like, we have to. There’s no doubt. We have to think differently,” Deborah Cline, DNP, RN, associate professor in the Department of Graduate Studies with Cizik School of Nursing at UTHealth Houston in Texas, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about oncology nurse retention. 

“I think the key in effective communication is building trust, because without trust, patients are not likely to engage in their care as effectively, which can influence patient well-being and their overall health outcomes. Building trust is, I think, crucial,” Deb Christensen, MSN, APRN, AGCNS-BC, AOCNS, founder and chief patient officer at the Cancer Help Desk, a nonprofit that provides personalized cancer treatment resources, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about strategies oncology nurses can use when approaching difficult conversations with patients across all populations.